Resolution criteria on PolyGram: This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
PolyGram is an on-chain prediction market where you trade YES or NO outcome shares with real USDC on Polygon. For this market, buy YES if you believe the event will happen, or NO if you think it won't. Your maximum loss is your stake — winning shares pay $1.00 each at resolution. Unlike sportsbooks, there is no house edge: prices are set by supply and demand from other traders and reflect the crowd's real-time probability.
Market outcomes
| Hantavirus vaccine in 2026? | 11% YES | 89% NO |
The FDA has not yet approved any vaccine against Hantavirus for human use in the United States, despite decades of research into the pathogen. Hantavirus Pulmonary Syndrome carries a mortality rate exceeding 35% in confirmed cases, whilst Haemorrhagic Fever with Renal Syndrome affects tens of thousands annually in Asia and Europe. The market settles YES only if full FDA approval occurs by 31 December 2026—a window of approximately two years from typical market creation.
Historical vaccine development timelines offer context for the 11% implied probability on Polymarket's order book. Most vaccines require 5–10 years from Phase I trials to licensure; even accelerated programmes rarely compress this below 3–4 years. Several Hantavirus vaccine candidates have entered clinical trials over the past decade—notably in South Korea and China—but none have advanced to late-stage FDA review. The absence of endemic transmission in North America has reduced commercial incentive for US regulatory pursuit, distinguishing Hantavirus from pathogens with broader geographic burden.
Traders should monitor announcements from manufacturers with active programmes, particularly any advancement to Phase III trials or FDA breakthrough designation requests. Clinical trial registries and regulatory agency communications represent the primary information sources; no major vaccine developer has publicly signalled imminent FDA submission. The compressed timeline means any approval would require either an existing candidate to accelerate dramatically through late-stage testing, or a new entrant to compress development substantially—both scenarios remain possible but statistically uncommon given historical precedent.
Resolution is handled by the UMA optimistic oracle on Polygon. A proposer submits the outcome, a two-hour dispute window opens, and if no one stakes a counter-claim the payout is final. Contested outcomes escalate to UMA token-holder voting. Payouts clear in USDC to the winning side.
The mechanics for trading "Hantavirus vaccine in 2026?" are the same as any other PolyGram event contract. Each YES share resolves to $1 if the event happens, or $0 if it doesn't. The current price between 0¢ and 100¢ is the market's probability estimate, set live by the order book.
$71K in lifetime turnover and $18K of resting liquidity puts this market in the above the median by volume for pandemics contracts on PolyGram. Order-book depth is modest — expect a couple of cents of slippage on $1k+ trades.
Last 24 hours alone saw $3K in turnover, consistent with the market's lifetime daily-average pace.
The market has been open for under a month — fresh enough that information asymmetry remains a real factor.
Higher-volume markets tend to have tighter spreads and faster price discovery — meaning the displayed YES/NO percentages are more likely to reflect the true crowd-implied probability rather than a single trader's directional view.
As of today, traders on Polymarket price this outcome at 11%. The number updates continuously as the order book clears. PolyGram mirrors the same live odds with locale-aware formatting and USDC settlement.
Resolution is handled by the UMA optimistic oracle on Polygon. A proposer submits the outcome, a 2-hour dispute window opens, and if uncontested the payout is final. Contested outcomes escalate to UMA token holders.
This prediction market is scheduled to close on 31 December 2026. After the resolving event occurs, settlement typically clears within 24 hours once the UMA optimistic oracle confirms the outcome. All payouts are in USDC on the Polygon network.
To trade on this prediction market, create a free PolyGram account at polygram.ink, deposit USDC via Polygon, and place a YES or NO order on the outcome you believe in. You can learn more on our how-it-works page. Your maximum loss is limited to your stake — there is no leverage or margin.
When the outcome is determined, winning YES shares pay out $1.00 each in USDC, while losing shares pay $0. Settlement is handled by the UMA optimistic oracle on Polygon — a proposer submits the result, a two-hour dispute window opens, and if uncontested, payouts are distributed automatically. You can withdraw your winnings to any Polygon wallet.
Prediction-market positions can lose 100% of staked capital. Outcomes are uncertain by definition — historical accuracy of crowd-implied probabilities is high in aggregate but not for any single market. PolyGram does not provide investment advice. Trade only with capital you can afford to lose.
Regulatory status varies by jurisdiction. Germany, the United States, and most EU countries treat Polymarket-style event contracts under one of three frameworks: financial derivative, gambling product, or unregulated novel asset. Consult local counsel before trading.
Explore more prediction market odds and trading opportunities on PolyGram: